IFNA1 and hepatocellular carcinoma: Some studies have shown that the risks of early HCC recurrence after viral eradication are similar between IFN-based and DAA therapies [9, 10], and, furthermore, Waziry et al. performed a meta-analysis and reported that HCC recurrence was not different between IFN-based and DAA therapies [11].